Timely Data Resources, Inc., Feb 2012
in development.
Q: What kind of sources are integrated into the IPD?
A: Our sources include both online and print-based texts, government reports, medical journals, trade journals, market investment reports
Greystone Associates, Nov 2010
and penetration barriers when administered orally, peptide and protein drugs continue to be developed almost exclusively for parenteral administration. These combination drug-device products, where the drug
Greystone Associates, Aug 2011
've been prescribed. The availability of approved drugs for neurological disorders with extended release profiles creates the potential to improve patient compliance by extending the time between dosing
Greystone Associates, Jan 2010
The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated
Greystone Associates, Dec 2009, Pages: 125
. To encourage drugdevelopers to perform clinical testing in pediatric age groups for drugs anticipated to be used for children, the FDA and the European Commission have adopted special rules and guidance
Future Medicine Ltd, June 2011, Pages: 104
, challenges facing the development of antimicrobial peptide antibiotics, targeting bacterial virulence factors and more FOREWORD
- Antimicrobial drug discovery
Alan Fairlamb, Stewart Cole
EDITORIAL
- How
Greystone Associates, May 2009, Pages: 100
Delivering drugs to the central nervous system presents unique challenges. But, drugdevelopers and researchers have discovered that delivering CNS therapeutic drugs via inhalation mitigates several
Future Medicine Ltd, Dec 2010, Pages: 49
of the peer-reviewed journal Biomarkers in Medicine includes 8 manuscripts highlighting the evaluation and use of biomarkers in medical practice and drugdevelopment. Numerous benefits are evident from
John Wiley and Sons Ltd, Sep 2010, Pages: 363
of Akina, Inc., specializing in drug delivery. Dr. Park is Editor-in-Chief of the Journal of Controlled Release among other journal and advisory board appointments. The recipient of the Controlled Release
Decision Resources, Inc., Nov 2011
faced intense regulatory scrutiny over their cardiovascular safety profiles.
Although drugdevelopment guidelines for obesity agents currently only stipulate one-year trials, agents with a cardiac
Future Science Ltd, Aug 2011, Pages: 92
This is Part 1 of two Special Focus Issues of the peer-reviewed journal Future Medicinal Chemistry, guest-edited by Dr Takushi Kaneko of the Global Alliance for TB DrugDevelopment (TB Alliance
Greystone Associates, Aug 2008, Pages: 85
companies are pursuing drugdevelopment programs based on immune factors and signaling proteins. We expect pipeline immune factor drugs that will be launched over the next four years to have a dramatic effect
Future Science Ltd, Aug 2011, Pages: 126
This is Part 2 of two Special Focus Issues of the peer-reviewed journal Future Medicinal Chemistry, guest-edited by Dr Takushi Kaneko of the Global Alliance for TB DrugDevelopment (TB Alliance
thinkBiotech LLC, Feb 2012
practices, making it an indispensable guide for those developing projects and careers, within this fast moving field.
Every issue of Journal of Commercial Biotechnology publishes forward-thinking regular
Datamonitor, Dec 2010, Pages: 285
A) in development for neurogenic bladder.
Your key questions answered
- What key strategies were implemented by companies to drive urinary incontinence drug uptake and will these remain viable over the next decade
Datamonitor, Dec 2010, Pages: 167
products
Highlights
- There are 134 drugs in development for non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC). Molecular targeted therapies constitute the bulk (73%) of the pipeline
Datamonitor, Dec 2010, Pages: 268
-registration for each indication. The markets are smaller than other indications but not all the unmet needs will be fulfilled providing commercial opportunities for drugdevelopers seeking to enter the markets
Datamonitor, Dec 2010, Pages: 124
overview
Drug profile
Development overview
Product positioning
SWOT analysis
Drug forecast to
BIBLIOGRAPHY
Journal papers and conference abstracts
Websites
Datamonitor
Datamonitor, July 2011, Pages: 72
obesity product profiles including latest clinical data and industry developments
- Understand the underlying reasons for Contrave’s suspension and the risk posed to other pipeline drugs
- Escalating
Renub Research, Sep 2011, Pages: 72
for current and future market players. In addition to increasing awareness, diagnosis and treatment, there is the need to develop new drugs that promote bone building. While the market awaits new growth, driven
